Mesenchymal stem cells: The new players in the pathogenesis of tuberculosis

Journal of Microbial and Biochemical Technology

Volumn 3, Issue 3, 2011, Pages

  Mittal, Rahul ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; HERMES ANTIGEN; INTERLEUKIN 6; NITRIC OXIDE; STEM CELL ANTIGEN 1; VASCULOTROPIN RECEPTOR 2;

CELL DIFFERENTIATION; CELL INFILTRATION; CELL KILLING; CELL MIGRATION; CELL PROLIFERATION; CELLULAR IMMUNITY; EDITORIAL; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL; MITOSIS INHIBITION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERSISTENT INFECTION; SPLEEN CELL; T LYMPHOCYTE; TUBERCULOSIS;

EID: 79959986622     PISSN: None     EISSN: 19485948     Source Type: Journal    
DOI: 10.4172/1948-5948.100000e3     Document Type: Editorial

References (21)

1. Furlow B (2010) Tuberculosis: a review and update. Radiol Technol 82: 33-52.
2. Barnes PF, Cave MD (2003) Molecular epidemiology of tuberculosis. N Engl J Med 349: 1149-1156.
3. Currey B, Quamruzzaman Q, Rahman M (2011) A millennial cover-up: tuberculosis deaths in South Asia. J R Soc Med 104: 2-4.
4. WHO, Global tuberculosis control: a short update to the 2009 report. WHO/HTM/TB/2009426, World Health Organization, Geneva (2009).
5. Hanekom WA, Lawn SD, Dheda K, Whitelaw A (2010) Tuberculosis research update. Trop Med Int Health 15: 981-989.
6. Tiruviluamala P, Reichman LB (2002) Tuberculosis. Annu Rev Public Health 23:403-426.
7. Iademarco MF, Castro KG (2003) Epidemiology of tuberculosis. Semin Respir Infect 18: 225-240.
8. Dheda K, Warren RM, Zumla A, Grobusch MP (2010) Extensively drugresistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am 24: 705-725.
9. Banerjee R, Schecter GF, Flood J, Porco TC (2008) Extensively drug-resistant tuberculosis: new strains, new challenges. Expert Rev Anti Infect Ther 6: 713-724.
10. Shenjie T, Qing Z, Jinming Y, Yidian L, Wei S, et al. (2011) Extensively drugresistant tuberculosis at a tuberculosis specialist hospital in Shanghai, China: Clinical characteristics and treatment outcomes. Scand J Infect Dis (In Press).
11. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, et al. (2011) Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 377: 147-152.
12. Raghuvanshi S, Sharma P, Singh S, Van Kaer L, Das G (2010) Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci U S A 107: 21653-21658.
13. Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8: 726-736.
14. Liu ZJ, Zhuge Y, Velazquez OC (2009) Trafficking and differentiation of mesenchymal stem cells. J Cell Biochem 106: 984-991.
15. Shi Y, Hu G, Su J, Li W, Chen Q, et al. (2010). Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 20: 510-518.
16. Panés J, Ordás I, Ricart E (2010) Stem cell treatment for Crohn's disease. Expert Rev Clin Immunol 6: 597-605.
17. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M (2009) Adiposederived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136: 978-989.
18. Ryu CH, Park SH, Park SA, Kim SM, Lim JY, et al. (2011) Gene Therapy of Intracranial Glioma using Interleukin 12-secreting Human Umbilical Cord Blood-derived Mesenchymal Stem Cells. Hum Gene Ther (in press).
19. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F 3rd. (2011) Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 29: 11-19.
20. García-Gómez I, Elvira G, Zapata AG, Lamana ML, Ramírez M, et al. (2010) Mesenchymal stem cells: biological properties and clinical applications. Expert Opin Biol Ther 10: 1453-1468.
21. Bergfeld SA, DeClerck YA (2010) Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 29: 249-261.